| Ytd | 56.91% | |
| 1y | 45.56% |
| Open | 8.74 | Prev Close | 8.56 | Low | 8.51 | High | 8.89 | Mkt Cap | 871.28M |
| Vol | 902.07K | Avg Vol | 1.69M | EPS | -1.88 | P/E | -4.71 | Forward P/E | -5.69 |
| Beta | 2.36 | Short Ratio | 9.40 | Inst. Own | 104.56% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 8.49 | 200-d Avg | 6.87 | 1yr Est | 17.38 |
SLDB News
Summary: U.S. stock futures mixed, Dow futures down 0.1%. AirSculpt Technologies shares fell 13.4% a
Solid Biosciences is transitioning from a speculative Duchenne gene therapy play to a multi-asset ra
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. T
Solid Biosciences Inc. (SLDB) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 202
CHARLESTOWN, Mass. , June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "C
CHARLESTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Co
- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt
- Initiation of Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind trial as part o
CHARLESTOWN, Mass. , May 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the "Co
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5
- Orphan drug designation from the European Commission underscores Solid's commitment to advance SGT
CHARLESTOWN, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “C
Shares of Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) shot up 5.5% on Thursday after Tru
Solid Biosciences Inc. (NASDAQ: SLDB - Get Free Report) has received an average recommendation of "M
Wall Street analysts changed ratings on top stocks. For insights on changes, see analyst ratings pag
- Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annu
Ally Bridge Group NY LLC cut its stake in shares of Solid Biosciences Inc. (NASDAQ: SLDB) by 24.1% i
Solid Biosciences Inc. (SLDB) Presents at Barclays 28th Annual Global Healthcare Conference Transcri
Solid Biosciences retains a "Strong Buy" rating, driven by robust interim data for SGT-003 in pediat
Solid Biosciences Inc. (NASDAQ: SLDB) shares are tumbling on Wednesday following a recent update reg
- 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust micr
FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capric
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer
Dow Jones falls 500 points on Friday, Marvell Technology shares jump 18.4%, other stocks recording g
'Secretary Kennedy Adds Duchenne Muscular Dystrophy, Metachromatic Leukodystrophy To Newborn Screeni
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biote
https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines
On Thursday, 369 companies hit new 52-week lows.
On Tuesday, 647 companies set new 52-week lows.
On Monday, 369 companies set new 52-week lows.
During Thursday's session, 406 companies made new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
During the session on Thursday, 461 stocks hit new 52-week lows.
During Tuesday's session, 275 companies made new 52-week lows.
Friday's session saw 225 companies set new 52-week lows.
On Thursday, 283 companies set new 52-week lows.
On Monday, 198 companies hit new 52-week lows.
Thursday's session saw 337 companies set new 52-week lows.
During Friday, 125 stocks hit new 52-week lows.
On Wednesday, 807 companies reached new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Wednesday's trading, 435 companies set new 52-week lows.